---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Himalayas-1"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Himalayas-1. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 36 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence/himalayas-1"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Himalayas-1

<a id="heading-3.1.1"></a>

## 3.1.1 Himalayas-1

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Primary objective: radiographic progression-free survival superiority

> “The primary objective of this study is to demonstrate superiority in radiographic progression free survival (rPFS) of the investigational arm of rinzimetostat + darolutamide combination versus physician's choice of control: ARPI (darolutamide or enzalutamide) or docetaxel.”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.1-2"></a>

#### Comparison evaluated in the trial

> “Himalayas-1 is evaluating whether rinzimetostat plus darolutamide improves outcomes compared with physician’s choice of an ARPI or docetaxel in patients with mCRPC previously treated with abiraterone”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Registry status and dates

| Study characteristic | Quoted record |
| --- | --- |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-08-03” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2030-09” |
| First posted | “2026-07-23” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.2-2"></a>

#### Planned sites and countries

> “Himalayas-1 is a global study planned across approximately 250 study sites in 25 countries”
> “Study initiated in July 2026”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.2-3"></a>

#### Announcement of trial initiation

> “today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-3.1.1.2-4"></a>

#### Anticipated primary endpoint readout relative to cash runway

> “Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat”

Source: [ORIC Pharmaceuticals second quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates/)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Randomized phase 3 design with physician's choice of control

| Study characteristic | Quoted record |
| --- | --- |
| Design | “Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Protocol number | “ORIC-944-05” |
| EU trial number | “2026-525340-15-00” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.3-2"></a>

#### Randomization and stratification

| Design element | Quoted record |
| --- | --- |
| Randomization | “Patients will be randomized 1:1 to receive rinzimetostat 400 mg QD plus darolutamide 600 mg BID, or prespecified physician’s choice of control (ARPI or docetaxel)” |
| Second randomization within the ARPI control | “If the prespecified control is ARPI, patients will undergo a second 1:1 randomization to darolutamide 600 mg BID or enzalutamide 160 mg QD” |
| Stratification factors | “Randomization will be stratified by prior docetaxel use in the metastatic castration-sensitive prostate cancer (mCSPC) setting, prespecified control category (ARPI versus docetaxel), and presence of hepatic metastases” |

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.3-3"></a>

#### Protocol finalized after end-of-phase 1 interactions with regulators

> “Following End-of-Phase 1 interactions with the FDA and other global health authorities, ORIC finalized the trial protocol and has initiated the Himalayas-1 global Phase 3 registrational trial.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-3.1.1.3-4"></a>

#### Sponsorship and darolutamide supply agreement

> “On July 7, 2026, the Company entered into a clinical trial collaboration and supply agreement with Bayer Consumer Care AG (Bayer)”
> “The Company will conduct and sponsor the Himalayas-1 trial and maintain full economic ownership and control of rinzimetostat.”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key inclusion criteria

> “Male patients aged ≥18 years”
> “Histologically or cytologically confirmed prostate adenocarcinoma without small cell features”
> “Progressive disease in the setting of surgical or medical castration, with evidence of disease progression as per PCWG3 on treatment with abiraterone ≥12 weeks in the mCSPC setting or first-line mCRPC setting”
> “Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan”
> “ECOG PS of 0 or 1”
> “Adequate organ function”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.4-2"></a>

#### Key exclusion criteria

> “Prior systemic anticancer therapy, beyond protocol-permitted abiraterone-based treatment and docetaxel in the mCSPC setting”
> “Radiotherapy within 2 weeks before randomization”
> “Known or suspected brain metastases or active leptomeningeal disease”
> “Clinically significant cardiovascular disease”
> “Active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.4-3"></a>

#### Excluded and permitted prior therapies in the registry record

> “Prior treatment for prostate cancer at any stage with cytotoxic chemotherapy, radioligand therapy (ie, 177Lu -PSMA-617, radium-223), ARPIs including apalutamide, darolutamide, and enzalutamide, PARP monotherapy or other systemic anticancer treatment (approved drugs or experimental compounds such as, antibody therapy, immunotherapy, gene or cell therapy, angiogenesis inhibitors, CDK4/6 inhibitors, PRC2 inhibitors) with the following exceptions:”
> “Treatment with first-generation antiandrogen agents (eg, bicalutamide, flutamide, nilutamide), but must be discontinued prior to the first dose of study medication”
> “Docetaxel treatment is allowed for mCSPC, as long as no signs of failure or disease progression occurred during treatment or within 3 months of treatment completion”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Investigational and control regimens

| Study drug and arm | Quoted dose and schedule |
| --- | --- |
| Rinzimetostat (investigational arm) | “400 mg once daily (QD)” |
| Darolutamide (investigational arm and physician's choice) | “600 mg twice daily (BID)” |
| Enzalutamide (physician's choice) | “160 mg once daily (QD)” |
| Docetaxel (physician's choice) | “75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.5-2"></a>

#### Rinzimetostat dosing with or without food

> “randomized 1:1 to receive the RP3D of 400 mg once daily rinzimetostat (with or without food) in combination with darolutamide versus physician’s choice of an androgen receptor (AR) inhibitor or docetaxel”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-3.1.1.5-3"></a>

#### Basis for the rinzimetostat dose

> “Phase 1b dose-optimization data supported selection of rinzimetostat 400 mg once daily (QD) in combination with darolutamide 600 mg twice daily (BID) for evaluation in Himalayas-1”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “The analysis demonstrated that 400 mg and 600 mg once daily provided comparable efficacy.”
> “Based on these findings 400 mg once daily in combination with darolutamide has been selected as the RP3D for rinzimetostat.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Radiographic Progression-free Survival by Blinded Independent Central Review as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Trial definition of radiographic progression-free survival

> “Radiographic Progression Free Survival is defined as the time from the date of randomization to first evidence of radiographic progression as assessed in soft tissue by RECIST 1.1 or in bone per PCWG3 guideline by BICR, or death, whichever occurs first”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-2"></a>

##### Assessment of the primary endpoint

> “BICR per RECIST v1.1 for soft-tissue disease or per PCWG3 criteria for bone disease, or death from any cause, whichever occurs first”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.6.1-3"></a>

##### Key secondary endpoint: overall survival

> “OS is defined as time from date of randomization to date of death due to any cause”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-4"></a>

##### Other secondary efficacy, safety, and pharmacokinetic endpoints

| Endpoint | Quoted registry definition |
| --- | --- |
| Objective response rate | “ORR is defined as proportion of patients with measurable soft tissue disease at baseline who have a confirmed objective response of complete response (CR) or partial response (PR)” |
| Duration of response | “DOR is defined as time of first response to first documentation of radiographic progression or death, whichever occurs first” |
| Prostate-specific antigen response | “Defined as the proportion of patients with a confirmed ≥50% and ≥90% decline in PSA from baseline as per the PCWG3 criteria, along with the maximum decline in PSA occurring at any point on study” |
| Time to PSA progression | “Measured from the start of treatment until criteria for PSA progression are met as per PCWG3” |
| Time to first symptomatic skeletal event | “Time from randomization to first symptomatic skeletal event (symptomatic bone fractures, spinal cord compression, surgery or radiation to the bone whichever is first)” |
| Adverse events | “Type, incidence, relationship to study treatments, severity, and seriousness of AEs” |
| Pharmacokinetics | “Rinzimetostat characterized by predose and postdose plasma concentrations at selected time points” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-5"></a>

##### Patient-reported outcome endpoints

| Domain | Quoted registry outcome measure |
| --- | --- |
| Pain | “Change from baseline in patient reported pain symptoms per Brief Pain Inventory-Short Form (BPI-SF)” |
| Health-related quality of life | “Change from baseline in health-related quality of life (HRQoL) per Functional Assessment of Cancer Therapy - Prostate (FACT-P)” |
| Health status | “Change from baseline in patient reported health status per European Quality of Life 5-Dimension 5 Level (EQ-5D-5L)” |
| Symptomatic toxicity | “Symptomatic toxicity as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE)” |
| Pain progression | “Time to confirmatory deterioration in patient-reported pain symptoms per BPI-SF Item 3” |
| Quality-of-life deterioration | “Time to definitive deterioration in patient-reported health related quality of life (HRQoL) per FACT-P” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-6"></a>

##### Consensus definition of radiographic progression-free survival

> “Radiographic progression-free survival (rPFS) is the time interval from random assignment to the date when the first site of disease is found to progress (using a manifestation-specific definition of progression), or death, whichever occurs first.”
> “Of particular note is the use of the 2+2 rule to distinguish flare from true progression in patients with osseous disease at baseline”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-3.1.1.6.1-7"></a>

##### Consensus position on the association with overall survival

> “The association between rPFS and overall survival is still being investigated, but an association was demonstrated in at least one of these trials.”
> “The suitability of efficacy end points to demonstrate clinical benefit is context dependent, and consultation with regulatory authorities is strongly recommended when selecting and defining end points for a trial intended to support drug approval.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-3.1.1.6.1-8"></a>

##### Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with abiraterone

> “Spearman's correlation coefficient between rPFS and OS was 0.72.”
> “These data make no surrogate claims of rPFS and do not provide support for the use of rPFS to serve as a substitute for OS at this juncture.”

Source: [Morris et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4881370/)

<a id="topic-3.1.1.6.1-9"></a>

##### Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with enzalutamide

> “Spearman ρ was 0.72 (95% CI, 0.67-0.76) among all patients, 0.89 (95% CI, 0.86-0.92) among enzalutamide-treated patients, and 0.53 (95% CI, 0.43-0.61) among placebo-treated patients.”
> “In our analysis, the lower correlation between rPFS and OS seen with placebo-treated patients than seen with enzalutamide-treated patients could be partly related to postprotocol exposure to life-prolonging therapy.”

Source: [Rathkopf et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885186/)

<a id="topic-3.1.1.6.1-10"></a>

##### Patient-level correlation with overall survival after prior androgen receptor pathway inhibitor and taxane

> “In the overall population, rPFS correlated strongly with OS (rho ≥ 0.7).”
> “Correlations between rPFS or OS and time to SSE without death were weak or mild.”

Source: [Morris et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11851234/)

<a id="topic-3.1.1.6.1-11"></a>

##### Trial-level surrogacy in first-line mCRPC naive to androgen receptor pathway inhibitors

> “Eleven RCTs were identified.”
> “Using the methodology recommended by the German health authority IQWiG, this study supports rPFS as a valid intermediate endpoint for OS in first-line ARPi naïve mCRPC.”

Source: [Castro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832950/)

<a id="topic-3.1.1.6.1-12"></a>

##### Trial-level surrogacy across advanced prostate cancer

> “A total of 143 randomized trials (n=75,601 patients) were included.”
> “radiographic PFS [n=52,548], 0.50 [95% CI, 0.35 to 0.63]”
> “Our aggregate screening method for surrogate end points in advanced prostate cancer showed that commonly used clinical end points are not clear valid surrogate end points for OS.”

Source: [Gharzai et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38320030/)

<a id="topic-3.1.1.6.1-13"></a>

##### Clinical progression without radiographic progression

> “Of 736 patients with disease progression, 280 (38%) had UCP-only and 124 (17%) had UCP plus RAD.”
> “Including UCP events lowered estimates of treatment benefit—median crPFS was 13.3 months (95% CI 11.1 to 13.8) versus median rPFS of 16.5 months (95% CI 13.8 to 16.8) in AAP group.”

Source: [Rao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7662417/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned randomized participants

> “Approximately 600 patients will be randomized 1:1 to rinzimetostat plus darolutamide versus physician’s choice of ARPI (1:1 to darolutamide or enzalutamide) or docetaxel”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment by sites and countries

> “The Himalayas-1 trial is expected to enroll approximately 600 patients from over 250 sites in 25 countries”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Planned primary analysis of radiographic progression-free survival

> “rPFS will be compared between treatment groups using a stratified log-rank test based on the three randomization stratification factors.”
> “The hazard ratio and corresponding 95% confidence interval will be estimated using a stratified Cox regression model, and Kaplan-Meier methods will be used to summarize rPFS”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Hierarchical testing of overall survival

> “OS will be formally tested only if the primary rPFS analysis is statistically significant and will be analyzed using corresponding stratified log-rank, Cox regression, and Kaplan-Meier methods”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: design and data limitations

- No Himalayas-1 results are available. The registry lists the trial as “Recruiting”, with an actual start of 2026-08-03 and estimated primary completion in 2028-03; the design information comes from the registry record, ORIC press releases and filings, and a trial-in-progress poster hosted on the ORIC website.
- The trial is open label, with no masking (“None (Open Label)”). The primary endpoint, rPFS, is assessed by blinded independent central review per RECIST 1.1 for soft tissue and PCWG3 for bone.
- The control is a prespecified physician’s choice of an ARPI or docetaxel. Participants assigned to the ARPI control undergo a second 1:1 randomization to darolutamide or enzalutamide, so darolutamide is given in the investigational arm and in part of the control arm; randomization is stratified by control category, prior docetaxel in mCSPC, and hepatic metastases.
- Overall survival is a key secondary endpoint, formally tested only if the primary rPFS analysis is statistically significant. A consensus statement describes the association between rPFS and overall survival as “still being investigated”; a trial-level analysis of 143 randomized trials in advanced prostate cancer concluded that commonly used clinical end points “are not clear valid surrogate end points for OS”, while an analysis of 11 randomized trials supported rPFS as a valid intermediate endpoint in first-line ARPI-naive mCRPC, a population that differs from the post-abiraterone population of Himalayas-1.
- Eligibility limits the population to participants with ECOG performance status 0 or 1 and adequate organ function, and excludes brain metastases, clinically significant cardiovascular disease, active inflammatory gastrointestinal disease, and prior treatment with ARPIs other than abiraterone, chemotherapy other than docetaxel for mCSPC, radioligand therapy, PARP monotherapy, or PRC2 inhibitors.
- The 400 mg dose was selected from phase 1b dose-optimization data in 18 participants at 400 mg and 15 at 600 mg. ORIC conducts and sponsors the trial, and Bayer supplies darolutamide.

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf); [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/); [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/); [Gharzai et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38320030/); [Castro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832950/); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="topic-3.1.1.9-2"></a>

#### Open-label design

> “A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)”
> “None (Open Label)”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.9-3"></a>

#### Prespecified physician's choice of control

> “Himalayas-1 (NCT07723248) is a global, randomized, open-label Phase 3 study evaluating rinzimetostat plus darolutamide versus a prespecified physician’s choice of ARPI or docetaxel control in approximately 600 patients with mCRPC previously treated with abiraterone”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
